138 related articles for article (PubMed ID: 22849846)
21. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease.
de Vos LC; Noordzij MJ; Mulder DJ; Smit AJ; Lutgers HL; Dullaart RP; Kamphuisen PW; Zeebregts CJ; Lefrandt JD
Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):131-8. PubMed ID: 23139292
[TBL] [Abstract][Full Text] [Related]
22. The impact of relapsing sterile icodextrin-associated peritonitis on peritoneal dialysis outcome.
Basile C; De Padova F; Montanaro A; Giordano R
J Nephrol; 2003; 16(3):384-6. PubMed ID: 12832738
[TBL] [Abstract][Full Text] [Related]
23. Unexplained hypotension and exertional dyspnea in a night-cycled peritoneal dialysis patient--a rare form of icodextrin hypersensitivity.
Onuigbo MA
Adv Perit Dial; 2014; 30():87-9. PubMed ID: 25338427
[TBL] [Abstract][Full Text] [Related]
24. The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients.
Nongnuch A; Davenport A
Br J Nutr; 2015 Apr; 113(7):1040-3. PubMed ID: 25761438
[TBL] [Abstract][Full Text] [Related]
25. Hypoglycemic coma in a diabetic patient on peritoneal dialysis due to interference of icodextrin metabolites with capillary blood glucose measurements.
Disse E; Thivolet C
Diabetes Care; 2004 Sep; 27(9):2279. PubMed ID: 15333503
[No Abstract] [Full Text] [Related]
26. Icodextrin-induced acute pancreatitis in a peritoneal dialysis patient: a case report and literature review
.
Rubinstein S; Franjul R; Surana S; Fogel J
Clin Nephrol; 2016 Nov; 86 (2016)(11):283-286. PubMed ID: 27616762
[TBL] [Abstract][Full Text] [Related]
27. Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells.
Wu J; Yang X; Zhang YF; Wang YN; Liu M; Dong XQ; Fan JJ; Yu XQ
Clin Vaccine Immunol; 2010 May; 17(5):757-63. PubMed ID: 20200188
[TBL] [Abstract][Full Text] [Related]
28. Relationship of skin autofluorescence to severity of retinopathy in type 2 diabetes.
Yasuda M; Shimura M; Kunikata H; Kanazawa H; Yasuda K; Tanaka Y; Konno H; Takahashi M; Kokubun T; Maruyama K; Sato N; Kakizaki M; Sato M; Tsuji I; Miyata T; Nakazawa T
Curr Eye Res; 2015 Mar; 40(3):338-45. PubMed ID: 24871684
[TBL] [Abstract][Full Text] [Related]
29. [False measurement of glucose during dialysis with icodextrin].
Husøy AM; Knudsen GR; Thierley M; Svarstad E
Tidsskr Nor Laegeforen; 2006 Sep; 126(17):2268-70. PubMed ID: 16967067
[TBL] [Abstract][Full Text] [Related]
30. Early quality of life benefits of icodextrin in peritoneal dialysis.
Guo A; Wolfson M; Holt R
Kidney Int Suppl; 2002 Oct; (81):S72-9. PubMed ID: 12230484
[TBL] [Abstract][Full Text] [Related]
31. Comparison between standard single chamber versus dual chamber low glucose degradation product peritoneal dialysis fluids.
Vareesangthip K; Vongsanim S; Fan S; Davenport A
Artif Organs; 2021 Jan; 45(1):88-94. PubMed ID: 32645750
[TBL] [Abstract][Full Text] [Related]
32. The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients.
Gobin J; Fernando S; Santacroce S; Finkelstein FO
Blood Purif; 2008; 26(3):279-83. PubMed ID: 18421212
[TBL] [Abstract][Full Text] [Related]
33. Icodextrin decreases technique failure and improves patient survival in peritoneal dialysis patients.
Wang IK; Li YF; Chen JH; Liang CC; Liu YL; Lin HH; Chang CT; Tsai WC; Yen TH; Huang CC
Nephrology (Carlton); 2015 Mar; 20(3):161-7. PubMed ID: 25487756
[TBL] [Abstract][Full Text] [Related]
34. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
Opatrna S; Popperlova A; Kalousová M; Zima T
Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
[TBL] [Abstract][Full Text] [Related]
35. Avoidable iatrogenic hypoglycemia in patients on peritoneal dialysis: the risks of nonspecific glucose monitoring devices and drug-device interaction.
Firanek CA; Jacob DT; Sloand JA
J Patient Saf; 2014 Dec; 10(4):218-21. PubMed ID: 23860196
[TBL] [Abstract][Full Text] [Related]
36. Peritoneal dialysis: new developments and new problems.
Gradden CW; Ahmad R; Bell GM
Diabet Med; 2001 May; 18(5):360-3. PubMed ID: 11472445
[TBL] [Abstract][Full Text] [Related]
37. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.
Smit AJ; Gerrits EG
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):527-33. PubMed ID: 20844429
[TBL] [Abstract][Full Text] [Related]
38. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.
Siriopol D; Hogas S; Veisa G; Mititiuc I; Volovat C; Apetrii M; Onofriescu M; Busila I; Oleniuc M; Covic A
Int Urol Nephrol; 2015 Mar; 47(3):563-9. PubMed ID: 25425437
[TBL] [Abstract][Full Text] [Related]
39. Icodextrin-induced acute generalized exanthematous pustulosis in a patient with peritoneal dialysis.
Liu CH; Chen CC; Sung CC
Nephrology (Carlton); 2024 Jul; 29(7):442-445. PubMed ID: 38599621
[TBL] [Abstract][Full Text] [Related]
40. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients.
Meerwaldt R; Hartog JW; Graaff R; Huisman RJ; Links TP; den Hollander NC; Thorpe SR; Baynes JW; Navis G; Gans RO; Smit AJ
J Am Soc Nephrol; 2005 Dec; 16(12):3687-93. PubMed ID: 16280473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
